NCT07407283 2026-04-21
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
NCT04846478 2025-04-17
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05567679 2023-09-22
A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer
Cedars-Sinai Medical Center
Phase EARLY_PHASE1 Withdrawn